PEOPLE - VNUS Medical Technologies makes appointment:
This article was originally published in Clinica
Executive Summary
Peter Osborne, who was appointed as interim CFO of VNUS Medical Technologies (San Jose, California) in October 2007, will remain in the position on a permanent basis and also becomes the vice-president of finance and administration. Mr Osborne is a former audit partner of Deloitte & Touche and has more than 25 years' executive financial experience. VNUS is a developer of devices for the minimally-invasive treatment of venous reflux disease.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.